CRISPR和Cas基因市场－全球产业规模、份额、趋势、机会及预测（按产品/服务、应用、最终用途、地区和竞争格局划分，2021-2031年）

全球 CRISPR 和 Cas 基因市场预计将从 2025 年的 29.1 亿美元成长到 2031 年的 74.6 亿美元，复合年增长率为 16.98%。

此领域涵盖基因组编辑解决方案的开发和推广，这些方案利用丛集规律间隔短回文重复序列（CRISPR）及其相关蛋白进行精确的DNA修饰。推动此市场发展的关键因素包括：需要治疗的先天性遗传疾病发生率不断上升，以及农业生物技术在提高作物抗性方面的迫切需求。此外，政府和私人机构持续的资金投入为研发提供了必要的资源，使其不受瞬息万变的技术潮流的影响，成为推动产业成长的根本动力。

然而，该市场在这些治疗方法的安全性方面面临着许多挑战，尤其是脱靶基因突变的风险，增加了监管核准流程的复杂性。这些技术难题需要严格且耗时的检验研究，可能会延迟治疗应用的商业性推出。儘管存在这些障碍，该领域依然蓬勃发展。美国基因与细胞治疗学会（ASGCT）指出，截至2024年，全球已有超过4,000种基因、细胞和RNA治疗方法正在研发中。如此庞大的候选疗法数量凸显了市场对精准基因编辑解决方案的强劲需求，前提是这些方案能够满足可靠的安全性和监管标准。

市场驱动因素

在生物技术产业，策略联盟和伙伴关係已成为全球CRISPR和Cas基因市场商业化的关键驱动力，因为各公司都在寻求整合智慧财产权和资本，以应对复杂的法规环境。大型製药企业越来越多地与专业的基因编辑公司达成许可协议，将后者的专有平台整合到开发平臺中，从而有效降低了早期研发阶段的高昂成本和风险。例如，2024年10月，Editas Medicine宣布其与DRI Healthcare Trust的策略合作已获得5,700万美元的预付款，这笔款项预支了与Vertex Pharmaceuticals合作专案未来的许可费，从而增强了其营运资金。此类合作对于将学术发现转化为可行的商业产品至关重要，并能帮助小规模的创新者获得实现其商业目标所需的永续资金。

同时，提升CRISPR技术疗效和安全性的技术进步解决了与脱靶效应和递送系统相关的关键挑战，扩大了其市场覆盖范围。体内编辑技术和先进递送载体的进步使得在患者体内进行精准基因修饰成为可能，推动了该行业从体外应用向全身治疗的转变。临床结果证实了这项转变。 2024年11月，Intella Therapeutics宣布，美国食品药物管理局（FDA）核准了该公司的临床实验（IND）申请，并启动了一项针对50名遗传性转甲状腺素类淀粉沉积症变性患者的单剂量体内疗法的关键性3期临床试验。该领域能够继续进行此类高风险研究，得益于其雄厚的资金实力。截至2024年11月，Vertex Pharmaceuticals在第三季末拥有112亿美元的现金和投资，为基因编辑药物的持续创新提供了坚实的财务基础。

市场挑战

脱靶基因突变的风险已成为全球CRISPR和Cas基因市场面临的重大阻碍因素，从根本上影响着该产业的成长速度。监管机构优先考虑病患安全，并要求提供全面的数据来检验基因编辑工具不会意外改变非标靶DNA序列。这项要求延长了临床前检验阶段，并显着延缓了新疗法候选药物的研发进程。因此，生物技术公司在启动人体临床试验之前，必须投入大量资源和时间进行全面的安全性评估，从而有效地减缓了从药物发现到临床应用的整个过程。

这些技术和监管障碍造成了漏斗效应，使得许多处于研发阶段的资产难以快速获得临床试验核准。这些严格的安全标准显然阻碍了研发管线的进展。根据再生医学联盟的数据，到2024年，全球市场上正在进行的临床试验总数预计仅年增3%。这种温和的成长率表明，与安全性相关的检验障碍直接限制了治疗方法走向商业化的数量，最终阻碍了市场的整体成长。

市场趋势

碱基编辑技术的广泛应用标誌着基因编辑技术向精准化迈出了重要一步，它能够在不造成双股DNA断裂的情况下进行单碱基替换。这项措施直接解决了传统编辑技术相关的安全隐患，降低了染色体重排的风险，并扩大了敏感组织中基因修復的范围。製造商正致力于利用这些先进平台开发针对复杂遗传疾病（例如血红蛋白病和α1-抗胰蛋白酶缺乏症）的根治性治疗方法。根据Beam Therapeutics公司于2024年8月发布的“2024年第二季度财务业绩报告”，该公司拥有雄厚的财务实力，并披露其拥有10亿美元的现金和证券，用于拓展其碱基编辑临床研究项目。

将人工智慧应用于RNA设计指导，正在为疗效预测和脱靶效应降低树立新的标准。借助深度学习演算法，科学家可以分析庞大的基因组库，并建立合成编辑系统，从而克服天然酵素的限制。这种计算策略显着加快了发现阶段，能够在生物学检验之前快速识别出高精度的候选基因。在2024年4月发布的「OpenCRISPR-1」计画中，Profluent公司利用基于110万个基因组序列训练的人工智慧模型，开发了首个开放原始码的、性能可与传统Cas9工具相媲美的AI基因编辑工具。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球CRISPR和Cas基因市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品/服务分类（产品（试剂盒/酵素、文库、设计工具、抗体等）、服务（细胞株设计、gRNA 设计、微生物基因编辑、DNA 合成））
  • 按应用领域（生物医学、农业）
  • 依最终用户（生技/製药公司、学术/政府研究机构、受託研究机构(CRO)）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美 CRISPR 和 Cas 基因市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲 CRISPR 和 Cas 基因市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区 CRISPR 和 Cas 基因市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲 CRISPR 和 Cas 基因市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美 CRISPR 和 Cas 基因市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球 CRISPR 与 Cas 基因市场：SWOT 分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• AstraZeneca plc
• Addgene
• Cellectis bioresearch Inc
• CRISPR Therapeutics Inc.
• Editas Medicine, Inc.
• F. Hoffmann-La Roche Ltd.
• Horizon Discovery Group plc
• Lonza Group AG
• GenScript Biotech Corporation
• Merck KGaA

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global CRISPR and Cas Genes Market is projected to expand from USD 2.91 Billion in 2025 to USD 7.46 Billion by 2031, reflecting a compound annual growth rate of 16.98%. This sector encompasses the creation and distribution of genome editing solutions that employ Clustered Regularly Interspaced Short Palindromic Repeats and related proteins to perform accurate DNA alterations. Key forces driving this market include the rising incidence of congenital genetic diseases requiring curative therapies and the urgent need for agricultural biotechnology to improve crop hardiness. Additionally, continuous financial investment from both government agencies and private institutions acts as a fundamental catalyst for industry growth, supplying essential resources for research and development independent of temporary technological trends.

However, the market faces a major obstacle concerning the safety profile of these instruments, particularly the danger of off-target genetic mutations, which adds complexity to the regulatory approval pathway. This technical challenge requires strict, time-intensive validation studies that can postpone the commercial launch of therapeutic applications. Demonstrating the breadth of sector activity despite these impediments, the American Society of Gene & Cell Therapy noted that in 2024, the global landscape comprised over 4,000 gene, cell, and RNA therapies under development. This substantial number of candidates highlights the strong demand for precise gene editing solutions, contingent upon successfully meeting safety and regulatory benchmarks.

Market Driver

Strategic alliances and partnerships within the biotechnology industry are emerging as a primary catalyst for commercialization in the Global CRISPR and Cas Genes Market, as firms aim to combine intellectual property and capital to manage complex regulatory environments. Major pharmaceutical companies are increasingly signing licensing deals with specialized gene-editing enterprises to incorporate proprietary platforms into their development pipelines, effectively lowering the significant costs and risks linked to early-stage research. For example, according to Editas Medicine in October 2024, the firm bolstered its operating capital by obtaining a $57 million upfront payment via a strategic arrangement with DRI Healthcare Trust to monetize future license royalties stemming from its partnership with Vertex Pharmaceuticals. These collaborations are crucial for transforming academic discoveries into viable commercial products, ensuring that smaller innovators possess the enduring funding needed to attain commercial goals.

Concurrently, technological improvements that boost CRISPR effectiveness and safety are widening the market's reach by solving major problems regarding off-target effects and delivery systems. Breakthroughs in in vivo editing and advanced delivery vectors now permit precise genetic changes directly within the patient, advancing the industry beyond ex vivo uses toward systemic functional treatments. This evolution is illustrated by clinical achievements; according to Intellia Therapeutics in November 2024, the U.S. FDA approved the company's Investigational New Drug application to begin a crucial Phase 3 trial for a single-dose in vivo therapy involving 50 adults with hereditary transthyretin amyloidosis. The sector's ability to sustain such high-stakes research is supported by substantial capital holdings; according to Vertex Pharmaceuticals in November 2024, the company closed the third quarter with $11.2 billion in cash and investments, offering a strong financial foundation for ongoing innovation in gene-edited medicines.

Market Challenge

The danger of off-target genetic mutations acts as a significant constraint for the Global CRISPR and Cas Genes Market, fundamentally affecting the speed of industry growth. Regulatory authorities, placing a premium on patient safety, require comprehensive data to verify that editing instruments do not accidentally modify non-target DNA sequences. This stipulation mandates extended preclinical validation stages, which considerably lengthens the development timeline for new therapeutic hopefuls. As a result, biotechnology companies must dedicate substantial capital and time to thorough safety profiling prior to commencing human trials, effectively delaying the progression from initial discovery to clinical implementation.

This technical and regulatory barrier generates a funnel effect, wherein a large quantity of research-stage assets faces difficulty in rapidly obtaining approval for clinical entry. The consequence of these strict safety criteria is apparent in the stalling of pipeline advancement. According to the Alliance for Regenerative Medicine, in 2024, the global sector registered only a 3% year-over-year rise in the total number of active clinical trials. This slight growth rate illustrates how safety-related validation hurdles directly limit the quantity of therapies progressing toward commercialization, thereby impeding the overall growth trajectory of the market.

Market Trends

The uptake of base editing technologies marks a crucial evolution toward precision, allowing for single-base alterations without causing double-strand DNA breaks. This movement directly tackles safety issues linked to conventional editing techniques by reducing the chance of chromosomal rearrangements, thus broadening the utility of gene correction for sensitive tissues. Manufacturers are intensely focusing on these sophisticated platforms to create curative therapies for intricate genetic disorders like hemoglobinopathies and alpha-1 antitrypsin deficiency. According to Beam Therapeutics in August 2024, in its 'Second Quarter 2024 Financial Results', the firm announced a robust balance sheet featuring $1.0 billion in cash and marketable securities to further its portfolio of base editing clinical initiatives.

The incorporation of artificial intelligence into guide RNA formulation is creating a new standard for predicting efficacy and minimizing off-target events. By utilizing deep learning algorithms, scientists can now examine vast genomic libraries to construct synthetic editing systems that overcome the constraints of naturally occurring enzymes. This computational strategy notably hastens the discovery stage, enabling the swift recognition of high-fidelity candidates before biological validation occurs. According to Profluent in April 2024, in the 'OpenCRISPR-1 Announcement', the enterprise employed an AI model trained on 1.1 million genomic sequences to produce the first open-source, AI-designed gene editor that rivals the performance of conventional Cas9 instruments.

Key Market Players

• AstraZeneca plc
• Addgene
• Cellectis bioresearch Inc
• CRISPR Therapeutics Inc.
• Editas Medicine, Inc.
• F. Hoffmann-La Roche Ltd.
• Horizon Discovery Group plc
• Lonza Group AG
• GenScript Biotech Corporation
• Merck KGaA

Report Scope

In this report, the Global CRISPR and Cas Genes Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

CRISPR and Cas Genes Market, By Product & Service

• Product (Kits & Enzymes, Libraries, Design Tool, Antibodies, Others)
• Service (Cell Line Engineering, gRNA Design, Microbial Gene Editing, DNA synthesis)

CRISPR and Cas Genes Market, By Application

• Biomedical
• Agricultural

CRISPR and Cas Genes Market, By End-use

• Biotechnology & Pharmaceutical Companies
• Academic & Government Research Institutes
• Contract Research Organizations (CROs)

CRISPR and Cas Genes Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global CRISPR and Cas Genes Market.

Available Customizations:

Global CRISPR and Cas Genes Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global CRISPR and Cas Genes Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product & Service (Product (Kits & Enzymes, Libraries, Design Tool, Antibodies, Others), Service (Cell Line Engineering, gRNA Design, Microbial Gene Editing, DNA synthesis))
  • 5.2.2. By Application (Biomedical, Agricultural)
  • 5.2.3. By End-use (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Contract Research Organizations (CROs))
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America CRISPR and Cas Genes Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product & Service
  • 6.2.2. By Application
  • 6.2.3. By End-use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States CRISPR and Cas Genes Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product & Service
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End-use
  • 6.3.2. Canada CRISPR and Cas Genes Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product & Service
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End-use
  • 6.3.3. Mexico CRISPR and Cas Genes Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product & Service
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End-use

7. Europe CRISPR and Cas Genes Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product & Service
  • 7.2.2. By Application
  • 7.2.3. By End-use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany CRISPR and Cas Genes Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product & Service
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End-use
  • 7.3.2. France CRISPR and Cas Genes Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product & Service
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End-use
  • 7.3.3. United Kingdom CRISPR and Cas Genes Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product & Service
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End-use
  • 7.3.4. Italy CRISPR and Cas Genes Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product & Service
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End-use
  • 7.3.5. Spain CRISPR and Cas Genes Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product & Service
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End-use

8. Asia Pacific CRISPR and Cas Genes Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product & Service
  • 8.2.2. By Application
  • 8.2.3. By End-use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China CRISPR and Cas Genes Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product & Service
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End-use
  • 8.3.2. India CRISPR and Cas Genes Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product & Service
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End-use
  • 8.3.3. Japan CRISPR and Cas Genes Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product & Service
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End-use
  • 8.3.4. South Korea CRISPR and Cas Genes Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product & Service
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End-use
  • 8.3.5. Australia CRISPR and Cas Genes Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product & Service
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End-use

9. Middle East & Africa CRISPR and Cas Genes Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product & Service
  • 9.2.2. By Application
  • 9.2.3. By End-use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia CRISPR and Cas Genes Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product & Service
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End-use
  • 9.3.2. UAE CRISPR and Cas Genes Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product & Service
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End-use
  • 9.3.3. South Africa CRISPR and Cas Genes Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product & Service
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End-use

10. South America CRISPR and Cas Genes Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product & Service
  • 10.2.2. By Application
  • 10.2.3. By End-use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil CRISPR and Cas Genes Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product & Service
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End-use
  • 10.3.2. Colombia CRISPR and Cas Genes Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product & Service
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End-use
  • 10.3.3. Argentina CRISPR and Cas Genes Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product & Service
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End-use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global CRISPR and Cas Genes Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AstraZeneca plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Addgene
• 15.3. Cellectis bioresearch Inc
• 15.4. CRISPR Therapeutics Inc.
• 15.5. Editas Medicine, Inc.
• 15.6. F. Hoffmann-La Roche Ltd.
• 15.7. Horizon Discovery Group plc
• 15.8. Lonza Group AG
• 15.9. GenScript Biotech Corporation
• 15.10. Merck KGaA

16. Strategic Recommendations

17. About Us & Disclaimer